SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Highlights Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-04-15			5-day change	1st Jan Change
10.00 ^CNY	+1.94%		-4.85%	-0.99%

04-13	Shanghai Shyndec Pharmaceutical Expects Up to 65% Decline in Q1 Attributable Profit; Shares Slide 6%	MT
04-07	Shanghai Shyndec Pharmaceutical Gets China Supplementary Drug Approval for Expectorant	MT

Highlights

04-13	Shanghai Shyndec Pharmaceutical Expects Up to 65% Decline in Q1 Attributable Profit; Shares Slide 6%	MT
04-07	Shanghai Shyndec Pharmaceutical Gets Regulatory Approval for Kidney Drug	MT
03-27	Shanghai Shyndec pharmaceutical 2025 net profit down 13.1% Y/Y	RE
03-25	Shanghai Shyndec Pharmaceutical Acquires Muscle Relaxant Market Authorization for 10.5 Million Yuan	MT
02-12	Shyndec Pharmaceutical Secures Bids For 51 Drugs in China's Latest Procurement Program	MT
02-09	Shyndec Pharmaceutical's Subsidiary Passes GMP Inspection	MT
01-27	Shanghai Shyndec Pharmaceutical's Attributable Profit Slides 13%	MT
01-26	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
12-12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
12-01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT
11-04	Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution	MT
25-10-29	Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd..	CI
25-10-29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-17	Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. for approximately CNY 110 million.	CI
25-09-01	Shyndec Pharma Obtains Drug Registration for Chest Pain Drug	MT
25-08-29	Shanghai Shyndec Pharmaceutical H1 net profit down 6.5% Y/Y	RE
25-07-18	Shyndec Pharmaceutical's H1 Profit Slips 7%, Total Revenue Drops 18%	MT
25-07-17	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-17	Shanghai Shyndec Pharmaceutical prelim H1 net profit down 6.5% Y/Y	RE
25-06-05	Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	MT
25-05-14	Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	MT
25-04-28	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug	MT
25-03-27	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI